Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Hemophilia A

Blood & Immune

Hemophilia A Clinical Trials and Treatments

Also called Factor VIII deficiency, classical hemophilia, X-linked hemophilia, Hemophilia Type A, Haemophilia A

Hemophilia A is an X-linked recessive inherited bleeding disorder resulting from deficiency or dysfunction of clotting factor VIII. Pathophysiology involves reduced or abnormal factor VIII protein function, which is critical for the intrinsic tenase complex in the coagulation cascade.

In plain words, hemophilia A is an inherited bleeding condition where the blood is missing enough of a clotting protein called factor VIII. As a result, people bruise easily and can bleed into their joints and muscles, causing pain and swelling.

Get an email when new Hemophilia A trials open or the FDA decides. Get alerts

Hemophilia A

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines17

Alhemo · Altuviiio · Hemlibra · Hympavzi · Qfitlia · 12 more

Hemophilia A has 17 FDA-approved medicines, 82 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Each date is the day a change was posted. Open an item to see where things stand now.

More about Hemophilia A

The condition manifests with easy bruising, spontaneous bleeding into joints (hemarthrosis) and muscles (intramuscular hematomas), and spontaneous bleeding in severe forms.

Keep reading about Hemophilia A

Clinical severity correlates directly with factor VIII levels: severe disease (<1% activity) causes spontaneous bleeding and hemarthrosis without provocation; moderate disease (1-5% activity) causes bleeding with minor trauma and significant joint problems; mild disease (5-40% activity) causes bleeding only with significant trauma or surgery.

Hemarthrosis leads to progressive arthropathy (arthritis, joint destruction) if untreated, with knees, elbows, and ankles most commonly affected. Intracranial hemorrhage and other serious bleeds represent major causes of morbidity and mortality.

Diagnosis is confirmed by factor VIII activity assay showing reduced levels. Most hemophilia A cases requiring regular treatment tend to be severe or moderate; mild cases may remain undiagnosed until a surgical or traumatic challenge reveals the bleeding tendency.

What are the symptoms of Hemophilia A?

These are common symptoms of Hemophilia A, and how strong they are varies from person to person.

  • Easy bruising and bleeding
  • Hemarthrosis (joint bleeds) causing pain and swelling
  • Muscle hematomas
  • Spontaneous bleeding in severe forms
  • Bleeding after trauma or surgery
  • Oral and GI bleeding

Who gets Hemophilia A?

Affects males predominantly due to X-linked inheritance; approximately 1 in 4,000-5,000 males worldwide carry the condition. Very rare in females, occurring only with homozygosity, compound heterozygosity, or skewed X-inactivation (lyonization).

Males with the variant can have mild, moderate or severe disease depending on how much factor VIII activity is left; carrier females occasionally have mild to moderate bleeding from unfavorable lyonization. All ethnicities and racial groups affected with similar prevalence. No geographic variation in incidence. Approximately 30% of cases represent de novo mutations. Family history essential for identification of carriers.

Next steps: find trials you might fitcompare treatmentsget help payingget alerts

Which medicines are FDA-approved for Hemophilia A?

There are currently 17 FDA-approved medications for Hemophilia A.

Side by sideCompare all 17 side by sideHow each of the medicines is taken, what the trials showed and the warnings on the label, in plain language.Open the comparison
Just prescribed one of these?Your first 90 days, step by stepWhat happens before the first fill, the tests and refills to expect, and help paying, with a one-page handout to print.
concizumab
Novo Nordisk
Search
efanesoctocog alfa
Your first 90 days
Sanofi (Bioverativ)
Search
emicizumab
Your first 90 days
Roche / Genentech
Official site
marstacimab
Pfizer
Search
fitusiran
Sanofi / Alnylam
Search
Advate
antihemophilic factor (recombinant)
Adynovate
antihemophilic factor (recombinant), pegylated
Afstyla
antihemophilic factor (recombinant), single chain
antihemophilic factor (recombinant), fc-vwf-xten fusion protein-ehtl
Your first 90 days
Cyklokapron
tranexamic acid (injection)
DDAVP Injection
desmopressin acetate
Eloctate
antihemophilic factor (recombinant), fc fusion protein
Esperoct
antihemophilic factor (recombinant), glycopegylated-exei
Feiba
anti-inhibitor coagulant complex
Humate-P
antihemophilic factor/von willebrand factor complex (human)
NovoSeven RT
coagulation factor viia (recombinant)
Wilate
von willebrand factor/coagulation factor viii complex (human)

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Hemophilia A medicines are in trials?

Investigational medicines Trial Friend tracks for Hemophilia A, with trial results, safety findings and where each one stands.

How to get help paying for Hemophilia A treatment

Charity funds and drugmaker programs for Hemophilia A, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · Hemophilia Federation of America
    Helping Hands Program fund
    Open

    Pays for: Emergency living expenses ($250 prepaid card, once per year; referral through HTC or member organization; does not cover medical bills, copays or premiums), up to $250 per year.

    The foundation says: “The Helping Hands program is now open on a limited basis for 2026. Due to funding constraints, a maximum of 20 requests will be approved…”
  • From a charity · TotalAssist (formerly PAN Foundation)
    Hemophilia fund
    Open

    Pays for: Out-of-pocket costs for approved medications, up to $12,500 per year. Requires health insurance (any kind).

  • From a charity · The Assistance Fund
    Hemophilia fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and fund for Hemophilia A, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Hemophilia A

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Hemophilia A resources

Reputable organizations and medical references for learning more about Hemophilia A, including disease registries, foundation resources, and clinical guidelines.

Recruiting now · study you can followRoche's phase 3 NXT007 study: get one email when it opens near you, and check its main requirements privately before talking with your doctor. →

Active clinical trials for Hemophilia A

Use this Hemophilia A clinical trial finder to see the 18 studies recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 14 test a treatment and 6 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

82 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT05568719

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Intervention: Testing of hepatic AAV Vector integration

Sponsor: Pfizer

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data colle...

Ages 18 Years+
Started Dec 2022Updated yesterdayEst. Feb 2040 (~13y 3m)
RecruitingTreatment trialPhase 4Recently updatedNCT05936580

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Intervention: Nuwiq

Sponsor: Octapharma

Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery

Ages 12 Years+
Started May 2026Updated 2 days agoEst. Feb 2027 (~3 months)
RecruitingTreatment trialPhase 4Recently updatedNCT05935358

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Intervention: Nuwiq

Sponsor: Octapharma

Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis

Ages 12 Years+
Started Nov 2023Updated 2 days agoEst. Dec 2026 (~1 month)
RecruitingObservational study, no treatment givenRecently updatedNCT07088458

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia A

Intervention: Damoctocog alfa pegol (Jivi, Bay94-9027)

Sponsor: Bayer

This is an observational study of children with mild, moderate, or severe hemophilia A who are receiving damoctocog alfa pegol, and are between 7 to <12 years of age at the time of enrolment. Observational studies use data that are collected as part of routine medical care and pa...

Ages 7 Years to 12 Years
Started Jul 2026Updated 5 days agoEst. Dec 2029 (~3y 1m)
RecruitingTreatment trialPhase 4Recently updatedNCT06941870

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

Intervention: Efanesoctocog alfa

Sponsor: Sanofi

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A.

Ages 12 Years+
Started Sep 2025Updated 1 week agoEst. Oct 2027 (~11 months)
Find Hemophilia A trials near you, ranked by distance →
Active trial locations46 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+38 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 3
Phase 4
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Hemophilia A trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Hemophilia A foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Hemophilia A patient communities

Facebook groups, Reddit communities and YouTube channels where Hemophilia A patients, caregivers and advocacy groups talk.

Hemophilia A news and guides

Trial Friend articles about Hemophilia A, newest first

Companies developing Hemophilia A treatments

Drugmakers that list Hemophilia A in their rare disease portfolio, with makers of its treatments first.

Questions people ask about Hemophilia A